A wide variety of clinically significant interactions occur between neoplastic and rheumatic diseases, and many are clinically significant.
Methods
The types of interactions between rheumatologic and neoplastic diseases and their clinical manifestations are reviewed and described.
Results
Several diseases included in the classic definition of rheumatology are associated with an increased incidence of specific neoplasms. Conversely, many neoplasms, by a variety of mechanisms, can cause or simulate many rheumatic diseases.
Conclusions
Knowledge of the increased propensity for neoplasia in certain conditions and of the possibility that cancer may be the cause of specific rheumatologic syndromes will assist the physician in providing optimal clinical care to affected patients.
Get full access to this article
View all access options for this article.
References
1.
MurrayG.C., PersellinR.H.Metastatic carcinoma presenting as monarticular arthritis: a case report and review of the literature. Arthritis Rheum.1980; 23: 95–100.
2.
ChakravartyK.K., WebleyM.Monarthritis: an unusual presentation of renal cell carcinoma. Ann Rheum Dis.1992; 51: 681–682.
3.
HoldrinetR.S., CorstensF., van HornJ.R.Leukemic synovitis. Am J Med.1989; 86: 123–126.
4.
CowleyM.D.Arthritic manifestations of leukemia. Intern Med.1986; 7: 202.
5.
FamA.G., VoorneveldC., RobinsonJ.B.Synovial fluid immunocytology in the diagnosis of leukemic synovitis. J Rheumatol.1991; 18: 293–296.
6.
SeleznickM.J., AguilarJ.L., RayhackJ.Polyarthritis associated with cutaneous T cell lymphoma. J Rheumatol.1989; 16: 1379–1382.
7.
CaldwellD.Musculoskeletal syndromes associated with malignancy. In: KelleyW.A., ed. Textbook of Rheumatology.4th ed.Philadelphia, Pa: WB Saunders; 1993: chap 94.
8.
CallenJ.P.Myositis and malignancy. Curr Opin Rheumatol.1989; 1: 468–472.
9.
SigurgeirssonB., LindelofB., EdhagO.Risk of cancer in patients with dermatomyositis or polymyositis: a population-based study. N Engl J Med.1992; 326: 363–367.
10.
LakhanpalS., BunchT.W., IlstrupD.M.Polymyositis-dermatomyositis and malignant lesions: does an association exist?Mayo Clin Proc.1986; 61: 645–653.
11.
DerooH., De BersaquesJ., NaeyaertJ.M.Paraneoplastic dermatomyositis in an adolescent. Dermatologica.1988; 174: 392.
12.
FukunagaH., EngelA.G., LangB.Passive transfer of Eaton Lambert myasthenic syndrome with IgG from man to mouse depletes presynaptic membrane active zones. Proc Natl Acad Sci U S A.1983; 80: 7636–7640.
13.
LambertE.H., EatonL.M., RookE.D.Defect of neuromuscular conduction associated with malignant neoplasms. Am J Physiol.1956; 187: 612.
14.
LambertE.H., RookE.D.Myasthenic state and lung Cancer. In: BrainW.R., NorrisF.H., eds. The Remote Effects of Cancer on the Nervous System.New York, NY: Grune & Stratton; 1965: 67–80.
15.
MillsJ.A.A spectrum of organ systems that respond to cancer: the joints and connective tissue. Ann N Y Acad Sci.1974; 230: 443–447.
16.
GreenN., Kuroharas, GeorgeFW3rd. The biologic behavior of lung cancer according to histologic type. Radiol Clin Biol.1972; 41: 160–170.
17.
YesnerR.Spectrum of lung cancer and ectopic hormones. In: SommersS.C., RosenP.P., eds. Pathology Annual. Vol 12. New York, NY: Appleton Century Crofts; 1978: 217–240.
18.
GoldstrawP., WalbaumP.R.Hypertrophic pulmonary osteoarthropathy and its occurrence with pulmonary metastases from renal carcinoma. Thorax.1976; 31: 205–211.
19.
MillerE.R.Carcinoma of the thymus with marked pulmonary osteoarthropathy. Radiology.1939; 32: 651–660.
20.
UllalS.R.Hypertrophic osteoarthropathy and leiomyoma of the esophagus. Am J Surg.1972; 123: 356–358.
HowardC.P., TelanderR.L., HoffmanA.D.Hypertrophic osteoarthropathy in association with pulmonary metastasis from osteogenic sarcoma. Mayo Clin Proc.1978; 53: 538–541.
23.
PapavasiliouC., PavlatouM., PappasJ.Nasopharyngeal cancer in pateints under the age of thirty years. Cancer.1977; 40: 2312–2316.
24.
EllouzR., CammounM., AttiaR.B.Nasopharyngeal carcinoma in children and adolescents in Tunisia: clinical aspects and the paraneoplastic syndrome. IARC Sci Publ.1978; 20: 115–129.
25.
RosenthallL., KirshJ.Observations on radionuclide imaging in hypertrophic pulmonary osteoarthropathy. Radiology.1976; 120: 359–362.
JohnsonJ.J., Leonard-SegalA., NashelD.J.Jaccoud's-type arthropathy: an association with malignancy. J Rheumatol.1989; 16: 1280.
32.
FreundlichB., MakoverD., MaulG.G.A novel antinuclear antibody associated with a lupus-like paraneoplastic syndrome. Ann Intern Med.1988; 109: 295–297.
33.
Sanchez-GuerreroJ., Gutierrez-UrenaS., VidallerA.Vasculitis as a paraneoplastic syndrome: report of 11 cases and review of the literature. J Rheumatol.1990; 17: 1458–1462.
34.
PetriM., FyeK.H.: Digital necrosis: a paraneoplastic syndrome. J Rheumatol.1985; 12: 800–802.
35.
LeslieB.M.Palmar fascitis and polyarthritis associated with malignant neoplasm: a paraneoplastic syndrome. Orthopedics.1992; 115: 36–39.
36.
BastenA., BonninM.Scleroderma in carcinoma. Med J Aust.1966; 1: 452–454.
37.
KhraishiM., HowardB., LittleH.A patient with Wernerís syndrome and osteosarcoma presenting as scleroderma. J Rheumatol.1992; 19: 810–813.
KurzrockR., CohenP.R.Erthromelalgia and myeloproliferative disorders. Arch Intern Med.1989; 149: 105–109.
41.
CaiQ., HodgsonS.F., KaoP.C.Brief report: inhibition of renal phosphate transport by a tumor product in a patient with oncogenic osteomalacia. N Engl J Med.1994; 330: 1645–1649.
42.
KassanS.S., ThomasT.L., MoutsopoulosH.M.Increased risk of lymphoma in sicca syndrome. Ann Intern Med.1978; 89: 888–892.
43.
AndersonL.G., TalalN.The spectrum of benign to malignant lymphoproliferation in Sjögren's syndrome. Clin Exp Immunol.1972; 10: 199–221.
44.
IsomakiH.A., HakulinenT., JoutsenlahtiU.Excess risk of lymphomas, leukemia, and myeloma in patients with rheumatoid arthritis. Ann Rheum Dis.1982; 41: 34–38.
45.
KellyC., SykesH.Rheumatoid arthritis, malignancy and paraproteins. Ann Rheum Dis.1990; 49: 657–659.
46.
GalliT., ChitiE.Rheumatoid arthritis and plasmacytosis. Ann Rheum Dis.1955; 14: 271–277.
47.
KellyC., BairdG., FosterH.Prognostic significance of paraproteinaemia in rheumatoid arthritis. Ann Rheum Dis.1991; 50: 290–294.
48.
RoummA.D., MedsgerT.A.Jr. Cancer and systemic sclerosis: an epidemiologic study. Arthritis Rheum.1985; 28: 1336–1340.
49.
LeeP., AlderdiceC., WilkinsonS.Malignancy in progressive systemic sclerosis: association with breast carcinoma. J Rheumatol.1983; 10: 665–666.
50.
KatzkaD.A., ReynoldsJ.C., SaulS.H.Barrett's metaplasia and adenocarcinoma of the esophagus in scleroderma. Am J Med.1987; 82: 46–52.
51.
VogelzangN.J., TorkelsonJ.L., KennedyB.J.Hypomagnesemia, renal dysfunction, and Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin. Cancer.1985; 56: 2765–2770.
52.
EpsteinE.Intralesional bleomycin and Raynaud's phenomenon. J Am Acad Dermatol.1991; 24: 785–786.
53.
HansenS.W., OlsenN., RossingN.Vascular toxicity and the mechanism underlying Raynaud's phenomenon in patients treated with cisplatin, vinblastine and bleomycin. Am Oncol.1990; 1: 289–292.
54.
WilliamsR.C.Jr, SibbettW.L.Jr, HusbyG.Oncogenes, viruses or rheumogenes?Am J Med.1986; 80: 1011–1016.
55.
RemmersE.F., SanoH., WilderR.L.Platelet-derived growth factors and heparin-binding (fibroblast) growth factors in the synovial tissue pathology of rheumatoid arthritis. Semin Arthritis Rheum.1991; 21: 191–199.
56.
HigleyH., PersichitteK., ChuS.Immunocytochemical localization and serologic detection of transforming growth factor beta 1: association with type I procollagen and inflammatory cell markers in diffuse and limited systemic sclerosis, morphea and Raynaud's phenomenon. Arthritis Rheum.1994; 37: 278–288.
